Potential of pre and probiotics in modulation of microbiome

Prof. M. Vidyavathi[1*], P. Naga Chandrika[2]

[1]*Department of Pharmaceutics, Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati, 517502, Andhra Pradesh.

[2]Department of Pharmaceutics, Geethanjali College of Pharmacy, Cheeryal, Kesara, Hyderabad, 501301, Telangana

Email: vidyavathi@spmvv.ac.in

Abstract:

An essential component of preserving physiological balance and overall health is the human microbiome. Dysbiosis, or imbalances in microbial populations, has been linked to a number of illnesses, such as cancer, metabolic syndromes, neurological conditions, and gastrointestinal issues. A promising method for reestablishing microbial balance and enhancing host health is the use of probiotics and prebiotics. While probiotics are live microbes that provide health advantages when given in sufficient proportions, prebiotics, which are mainly non-digestible carbohydrates, specifically promote the growth and activity of advantageous gut microorganisms. The processes via which probiotics and prebiotics alter the microbiome are outlined in this article along with data from recent studies that suggests they may be therapeutically beneficial. Future prospects and obstacles in microbiome-targeted medicine are also discussed.

Keywords: Probiotics, Prebiotics, Microbiome, synbiotics, and physiological balance

1. Introduction

Over the past two decades, interest has exploded in using prebiotics (compounds that feed beneficial microbes), probiotics (live microorganisms that provide health benefits), and combinations thereof (synbiotics) to intentionally reshape the microbiome and improve health outcomes. This article reviews definitions and mechanisms, summarizes the clinical and mechanistic evidence across major disease areas, discusses safety and regulatory issues, outlines practical considerations for use, and highlights research gaps and future directions. Key claims are supported with recent, high-quality reviews and meta-analyses.

1.1. Definitions and basic concepts

1.1.1. Prebiotics

Historically defined as “non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of beneficial bacteria in the colon,” as per functions, a prebiotic is any compound that is *utilized by the microbiota* to produce a health or performance benefit. Common examples include inulin-type fructans, galacto-oligosaccharides (GOS), and certain resistant starches. These substrates are fermented by microbes into metabolites (notably short-chain fatty acids — SCFAs) that exert local and systemic effects.

1.1.2. Probiotics

Probiotics are live microorganisms (bacteria or yeasts) which, when administered in adequate amounts, confer a health benefit on the host. Typical strains belong to genera such as *Lactobacillus* (now reclassified into multiple genera including *Lacticaseibacillus*, *Limosilactobacillus*), *Bifidobacterium*, *Saccharomyces*, and others. Crucially, probiotic effects are strain-specific, one strain's benefit cannot be automatically generalized to another.

1.1.3. Synbiotics and postbiotics

Synbiotics combine probiotics and prebiotics to enhance survival and colonization of the live microbes; postbiotics describe inactivated microbial components or metabolites (e.g., SCFAs, bacteriocins) that can have biological activity without containing live organisms.

2. Mechanisms of microbiome modulation

The potential of pre- and probiotics emerges from several mechanistic pathways:

a. Selective nutrient competition and enrichment

Prebiotics selectively feed beneficial taxa (e.g., *Bifidobacterium*), increasing their abundance and metabolic output (SCFAs). Probiotics may colonize transiently, occupy ecological niches, and compete with pathogens for nutrients and attachment sites.

b. Production of bioactive metabolites

Fermentation of prebiotics yields SCFAs (acetate, propionate, butyrate) that strengthen epithelial barrier function, modulate immune cells, and influence host metabolism and appetite signaling. Probiotic strains can also produce bacteriocins, lactic acid, and other small molecules that inhibit pathogens.

c. Barrier and immune modulation

Both pre- and probiotics can enhance mucus production, tight-junction integrity, and induce anti-inflammatory cytokines or regulatory T-cell responses while suppressing pro-inflammatory pathways.

d. Cross-feeding and community remodelling

A prebiotic may boost one taxon that produces metabolites used by other beneficial microbes (cross-feeding), leading to community-level shifts that outlast the direct presence of a probiotic strain.

e. Modulation of distant organs (gut–organ axes)

Microbial metabolites and immune signalling can affect the liver (gut–liver axis), brain (gut–brain axis), skin, and lungs.

3. Evidence of clinical benefits

The literature is large and growing; results vary by indication, population, strain, dose, and outcome measure. Synthesized findings across major areas are shown in *figure 1*, and discussed below:

a. Metabolic and cardiometabolic health

Clinical trials and meta-analyses suggest modest benefits of prebiotics, probiotics, and synbiotics on body weight, insulin sensitivity, lipid profiles, and markers of inflammation — but effects are generally small and variable.



Figure 1. Clinical benefits

b. Gastrointestinal disorders

Antibiotic-associated diarrhea (AAD) and **Clostridioides difficile (C. difficile)**: Certain probiotics (e.g., *Saccharomyces boulardii*, *Lactobacillus rhamnosus* GG) reduce the risk of AAD, and microbiome-based therapeutics (e.g., spore-formulated consortia) have shown promise in preventing recurrent C. difficile infection.

Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): Some probiotic strains and synbiotics improve symptoms in IBS; evidence in IBD is more mixed and often strain-specific. For ulcerative colitis maintenance, certain multistrain preparations (e.g., *E. coli* Nissle in some contexts) have comparable efficacy.

c. Immune system and infections

Probiotic supplementation has been associated with reduced duration and severity of some upper respiratory infections and may modulate vaccine responses in certain populations (e.g., elderly).

d. Mental health and the gut–brain axis (Neuro psychiatric disorders)

Preclinical studies and small human trials suggest probiotics (sometimes called "psychobiotics") can reduce anxiety and depressive symptoms in select cohorts. Mechanisms likely involve immune modulation, vagal signalling, and microbial metabolites influencing neurotransmitter systems.

Table 1: Comparison of microbiome and pro &prebiotics

Aspect	Microbiome	Prebiotics	Probiotics
Definition	The complete collection of microorganisms (bacteria, fungi, contagions, archaea) and their genes	Non-digestible food constituents that widely stimulate the growth or exertion of salutary microorganisms	Live microorganisms, which, when administered in acceptable quantities, confer health benefits to the host.
Measured by	16S rRNA sequencing- Shotgun metagenomics- Metatranscriptomics, metabolomics	Salutary input analysis- In vitro turmoil models dimension of SCFA product and bacterial growth response	Feasible cell count (CFU)- Strain identification via molecular typing- Clinical efficacy studies
Importance	Maintains metabolic balance, vulnerable function, and complaint resistance; influences digestion, mood, and overall health.	Nourishes salutary bacteria and supports a balanced microbiome ecosystem.	Restores microbial balance, prevents pathogen colonization, and enhances vulnerable defense
Dynamic Nature	largely dynamic; composition changes with diet, antibiotics, age, stress, and terrain.	Prebiotic efficacy varies with diet composition and host microbiota birth.	Colonization is frequently temporary; goods depend on strain, lozenge, and host conditions.
Examples	Gut microbiota dominated by Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria.	Inulin, Fructo-oligosaccharides (FOS),Galacto-oligosaccharides (GOS), Resistant bounce.	*Lactobacillus rhamnosus, Bifidobacterium longum, Saccharomyces boulardii, Lactobacillus acidophilus*
Composition	Billions of microbial species forming a complex ecosystem in the gut; balance between salutary and pathogenic microbes.	Complex carbohydrates and filaments resistant to digestion by host enzymes.	Specific strains of salutary bacteria or incentive formulated in foods or supplements.
Function	Abridgments undigested carbohydrates- Produces SCFAs and vitamins- Modulates vulnerable and metabolic pathways- Maintains intestinal hedge and gut – brain communication	Stimulates salutary bacteria (e.g., Bifidobacteria, Lactobacilli)- Enhances SCFA product- Reduces dangerous bacteria- Improves mineral immersion and vulnerable regulation	Competes with pathogens- Produces antimicrobial substances- Strengthens intestinal hedge- Regulates vulnerable and seditious responses- Modulates gut- brain signaling

e. Other areas (skin, oral, vaginal health)

Topical and oral probiotics are being explored for acne, atopic dermatitis, oral dysbiosis, and bacterial vaginosis.

4. The link between microbiome and pro& prebiotics (composition vs. Function)

The detailed comparison is listed in Table 1.

5. Factors that influence response to pre/probiotic interventions

The responses with the use of pre and probiotics vary so much due to many key determinants include:

- Baseline microbiota composition
- Host genetics, diet and lifestyle:
- Age and immune status:
- Strain-specific properties and dose:
- Duration and timing

6. Safety, quality control, and regulatory landscape of pre and probiotics

Safety. Evidence-based safety evaluations must be conducted at the strain level. Important components include: a precise taxonomic identification (genus, species, strain) with deposition in a recognized culture collection; a history of use or formal safety assessment documenting the absence of virulence factors; antibiotic-resistance profiling (and proving non-transferability in cases where resistance is detected); and toxicology/safety data

Quality control. Employ a blend of genotypic techniques (whole genome sequencing or strain-specific PCR/MLST) alongside phenotypic assessments. Log accession numbers for submitted strains of potency / viability, purity / contaminants, stability, and labeling

Regulation. Global benchmark: FAO/WHO (2002) continues to be the essential guideline for assessing probiotics in food (strain identification, safety, functional proof). Utilize it as the foundational concept.

7. Steps for preparation of probiotics and prebiotics: are shown in *figure 2*.

A. Preparation of probiotics:

i.Strain selection

Species and strain matters. Health effects are strain-specific, choose strains with documented safety and mechanism of action relevant to the intended indication (adhesion, acid/bile tolerance, antimicrobial production, immune modulation). Well-established strains (e.g., *Lacticaseibacillus rhamnosus* GG, *Bifidobacterium* spp., *Saccharomyces boulardii*) have extensive human data and often patents/licensing history.

ii. Characterization and safety testing

Genomic sequencing (to identify beneficial genes and screen for virulence/antibiotic-resistance determinants), antibiotic resistance profiling, and in vitro tests (acid/bile tolerance, adhesion, metabolite production) are standard. Regulatory dossiers increasingly expect genomic safety evidence.

iii. Cultivation and scale-up

Media optimization for yield and desired phenotype, anaerobic or microaerophilic fermentation (depending on strain), control of growth phase (log vs stationary — impacts stress resistance), and downstream processing (harvesting, washing) are critical.

Cryoprotectants and stabilizers (e.g., trehalose, skim milk, polyols) are used pre-freeze to improve survival during drying and storage.

iv. Downstream processing and formulation

Cell concentration and drying: Lyophilization (freeze-drying), spray-drying, and fluid-bed drying are common. Lyophilization often gives superior viability but is costlier. Protective excipients (sugars, proteins) are essential.

Encapsulation / microencapsulation protects from gastric acidity and bile; techniques include alginate beads, lipid matrices, polymer coatings, enteric capsules are used. Microencapsulation can increase delivery to the colon and shelf life.

Carrier formats: capsules, sachets, fermented foods, beverages, chewables are common formats used. Food matrix and processing (heat, pH) strongly affect viability; so strain–matrix compatibility must be validated.

v. Dosing and labeling

Quantification: Expressed as colony-forming units (CFU) at end of shelf life; stability studies must support label claims. Regulatory bodies differ on labeling rules and acceptable claims. The FDA issued draft guidance on quantitative labeling of live microbials in supplements — a practical but nonbinding guidance in many jurisdictions.

B. Preparation of prebiotics:

i. Types and sources

Fructans (inulin, FOS), galacto-oligosaccharides (GOS), resistant dextrins, resistant starches, human milk oligosaccharides (HMOs), polyphenol-derived oligosaccharides, and novel synthetic substrates fall under modern prebiotic categories. The ISAPP definition allows non-carbohydrate substrates as well.

ii. Manufacturing

Extraction from natural sources: Inulin/fructans from chicory, GOS via enzymatic conversion of lactose, resistant starches processed from cereals/tubers.

Enzymatic synthesis and chemoenzymatic methods used to make defined oligosaccharides like HMOs or designer oligosaccharides with specific linkages to selectively stimulate target microbes. Scale, cost, and purity are important constraints.

iii. Formulation considerations

Compatibility with probiotics (synbiotics): Combining prebiotics with compatible probiotic strains (synbiotics) can enhance survival and synergize effects — formulation must ensure stability and prevent premature fermentation or interactions during storage.

Delivery forms: These are incorporated into infant formula (HMOs), foods (fortified cereals, yogurts), supplements (powders, capsules). Palatability, dose and fermentation profile (gas production) must be managed clinically.



Figure 2. Preparation of pro and prebiotics

8. Emerging trends and novel strategies

a. Rationally designed consortia and next-generation probiotics (NGPs)

Instead of single strains, multi-species consortia designed to restore ecosystem function (e.g., butyrate producers) are being developed and clinically tested to improve survival through the GI tract.

b. Synbiotics tailored to ecology

Pairing a probiotic with a substrate that selectively boosts it (or its functional partners) enhances engraftment and effect — a targeted "seed + feed" approach.

c. Personalized microbiome therapeutics

Given the importance of baseline microbiota, personalized selection of pre/probiotics based on individual microbiome profiles is gaining traction.

d. Postbiotics and defined metabolites

Using microbial metabolites or inactivated cells avoids some safety/regulatory hurdles of live organisms

e. Microbiome-based adjuvants for vaccines and cancer immunotherapy

Evidence suggests the microbiome can modulate immune responsiveness to vaccines and checkpoint inhibitors; synbiotic strategies to boost vaccine immunogenicity are under study.

9. Practical recommendations

For clinicians:

- Use of evidence-based, strain-specific recommendations where available (e.g., *S. boulardii* or *L. rhamnosus* GG for prevention of AAD in appropriate contexts).
- Be cautious in recommending generalized probiotic supplements for complex diseases without robust strain-specific data.

For researchers:

- Prioritizing well-powered, randomized, strain-defined trials with functional endpoints (metabolomics, immune markers), longer follow-up, and characterization of baseline microbiomes.

For consumers:

- Preferring products with strain-level labelling, documented CFU counts, stability data, and evidence from human trials.
- Fermented foods (yogurt, kefir, kimchi) provide live microbes and can be part of a healthy diet, but their strains differ from therapeutic strains studied in trials.

10. Limitations, controversies, and research gaps

- **Heterogeneity of studies.** Different strains, doses, delivery formats, and outcome measures complicate meta-analyses and guideline formation.
- **Transient engraftment vs. lasting change.** Many probiotics do not permanently colonize the gut; understanding how transient changes produce lasting host benefits is an open question.
- **Placebo and expectation effects.** Symptoms like bloating and subjective well-being are sensitive to placebo influences; rigorous blinding is essential.
- **Safety in vulnerable populations.** More data are needed in neonates, the elderly, and immunocompromised persons.
- **Microbiome–drug interactions.** Microbiome modulation may alter drug metabolism (e.g., digoxin, levodopa); this area requires more translational research.

11. Challenges and future perspectives

Despite tremendous advancements, several kinds of obstacles still exist:

- **Strain specificity:** Probiotic effects vary by strain; not all strains are advantageous.
- **Survivability:** A lot of probiotic organisms are unable to withstand the acidity of the stomach.
- **Individual variability:** Diet and host genetics affect how the microbiota reacts.
- **Regulatory concerns:** Because probiotics are frequently categorized as supplements, there are differing requirements for quality.
- **Long-term safety:** To evaluate chronic use, more longitudinal research is required.

Future studies should focus on postbiotics (healthy, non-viable microbial metabolites), next-generation probiotics (such as *Faecalibacterium prausnitzii* and *Akkermansia muciniphila*), and a tailored diet.

12. Conclusion

Prebiotics and probiotics — alone or combined as synbiotics — offer promising avenues to modulate the microbiome for health. Mechanistic plausibility is strong (selective feeding, metabolite production, barrier and immune effects), and clinical benefits are established for certain indications (e.g., AAD prevention, recurrent C. difficile prevention with defined therapeutics). The most convincing future lies in targeted, ecology-informed, and evidence-based interventions: defined microbial consortia, synbiotics tailored to microbial ecology, and metabolite-focused therapies guided by multi-omics biomarkers. Continued high-quality clinical trials and improved standardization will determine how far the promise of microbiome modulation will translate into routine clinical practice.

13. References:

1. Smolińska S, Popescu FD, Zemelka-Więcek M. A review of the influence of prebiotics, probiotics, synbiotics, and postbiotics on the human gut microbiome and intestinal integrity. *J Clin Med.* 2025;14(11):3673.
2. Chatterjee S, Jadhav T, Patil M, et al. Effects of prebiotic, probiotic or synbiotic supplementation on overweight/obesity indicators: an umbrella review of meta-analyses. *Front Endocrinol (Lausanne).* 2024;15:1277921.
3. Asad A, Kirk M, Zhu S, Dong X, Gao M. Effects of Prebiotics and Probiotics on Symptoms of Depression and Anxiety in Clinically Diagnosed Samples: Systematic Review and Meta-analysis of Randomized Controlled Trials. Nutr Rev. 2025 1;83(7):e1504-e1520.
4. Wang X, Li H, Xu Y, et al. Effects and mechanisms of probiotics, prebiotics, synbiotics and postbiotics on intestinal health and disease. *Front Cell Infect Microbiol.* 2024;14:1430312.
5. Mohammadi A, Faghih M, Hosseini SA, et al. The use of probiotics and prebiotics in decolonizing pathogenic bacteria from the gut: a systematic review and meta-analysis. *Microb Pathog.* 2024;192:107446.
6. Wang R, Song Y, Zhang M, et al. Oral synbiotics modulate gut microbiota composition and inflammatory biomarkers in healthy adults: a systematic review and meta-analysis. *Nutrients.* 2024;16(3):495.
7. Markowiak P, Śliżewska K. Health benefits of prebiotics, probiotics, synbiotics, and postbiotics. *Nutrients.* 2024;16(22):3955.
8. Gibson GR, Probert HM, Rastall RA. Prebiotics and the modulation of gut microbiota: emerging directions in clinical nutrition. *Trends Food Sci Technol.* 2023;138:25-37.
9. Hill C, Calder PC, Guarner F, et al. Probiotics and the human host: mechanisms and clinical applications. *Nat Rev Gastroenterol Hepatol.* 2022;19(9):553-571.
10. Plaza-Díaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. *Adv Nutr.* 2020;11(3):725-738.